Group 1 - The core viewpoint of the news is that Yijiahe's stock has experienced fluctuations, with a recent decline of 2.01% and a current market value of 6.528 billion yuan [1] - Yijiahe's main business involves the research, production, and sales of special robot products, integrating technologies such as mobility, perception, operation, artificial intelligence, and data analysis, targeting industries like electricity, firefighting, new energy, and rail transportation [1] - The company's revenue composition includes 57.01% from robot products, 25.28% from smart grid and automation equipment, 15.33% from other services, and 2.38% from drone inspection services [1] Group 2 - As of September 30, Yijiahe reported a revenue of 356 million yuan for the first nine months of 2025, a year-on-year decrease of 11.24%, while the net profit attributable to shareholders was -42.32 million yuan, an increase of 47.26% year-on-year [2] - The company has distributed a total of 169 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3] - Institutional holdings show that as of September 30, 2025, the top ten circulating shareholders include the Huaxia CSI Robot ETF, which increased its holdings by 637,300 shares, and the Hong Kong Central Clearing Limited, which is a new shareholder with 3.0473 million shares [3]

Group 1 - The company has collected over 1 million hours of data from more than 3,000 households using Gen DAS Gripper and the industry's first large-scale data production line, Gen ADP, accelerating the development of the embodied industry [1] - The overall industry volume and individual skill scale are the largest, with a cumulative duration exceeding 10,000 hours and a total data scale of over 1 million clips, ensuring each skill has the highest data volume in the industry [1] - The data collection focuses on 10 common household scenarios and 30 skills, ensuring quality by avoiding excessive dispersion [1] Group 2 - The data includes multi-modal, high-quality information such as large FOV raw images, trajectories, annotations, and joint actions, with industry-leading accuracy and quality [1] - The first phase of data has been uploaded, covering 12 skills across 4 major scenario tasks, with plans to complete the remaining skills and provide support for data format conversion and usage [2] - The data is available for download at a specified link, and users are encouraged to provide feedback and suggestions for additional scenarios and skills to be digitized [2]

1月6日，亿嘉和（维权）盘中下跌2.02%，截至10:39，报32.01元/股，成交3.20亿元，换手率4.76%，总 市值65.79亿元。 资金流向方面，主力资金净流出2971.73万元，特大单买入1047.16万元，占比3.27%，卖出1898.53万 元，占比5.93%；大单买入6217.07万元，占比19.43%，卖出8337.44万元，占比26.06%。 亿嘉和今年以来股价涨7.78%，近5个交易日涨7.20%，近20日涨4.64%，近60日跌3.29%。 资料显示，亿嘉和科技股份有限公司位于江苏省南京市雨花台区创思路5号，成立日期1999年4月6日， 上市日期2018年6月12日，公司主营业务涉及主要从事特种机器人产品的研发、生产、销售及相关服务, 充分融合移动、感知、操作、人工智能、数据分析等机器人相关技术,面向电力、消防、新能源、轨道 交通等行业领域,提供多样化的智能产品、智能服务和系统解决方案。主营业务收入构成为：机器人产 品57.01%，智能电网设备及智能自动化设备25.28%，其他(补充)15.33%，无人机巡检服务2.38%。 分红方面，亿嘉和A股上市后累计派现1.69亿元。近三年，累 ...

Group 1: Regulatory Developments - The National Healthcare Security Administration (NHSA) is seeking public opinions on the draft guidelines for the real-world comprehensive value assessment of medical services, aiming to establish a unified evaluation system across the country [1] - CanSino Biologics has received approval for clinical trials of its 24-valent pneumococcal polysaccharide conjugate vaccine, which targets major circulating serotypes and is intended for individuals aged 2 months and older [2] - Merck has announced that its breakthrough therapy, Sotatercept, has been approved in China for treating adult patients with pulmonary arterial hypertension (PAH), based on data from the STELLAR Phase III clinical trial [3] - ST. Renfu has received approval for clinical trials of HW221043 tablets, intended for the treatment of advanced solid tumors, with no similar drugs currently approved in the market [4] - Heng Rui Medicine has received approval for clinical trials of HRS-4357 injection and HRS-5041 tablets, aimed at treating PSMA-positive prostate cancer [5] Group 2: Market Activities - Shenzhou Cell has received approval from the China Securities Regulatory Commission for its application to issue stocks to specific investors [6] - Tianchen Medical has signed a strategic cooperation agreement with Inspur Digital Technology to promote innovation in medical intelligent manufacturing and robotics [7] - Zhonghong Medical's subsidiary has participated in a bidding project for centralized procurement of medical consumables, with some products expected to be selected, enhancing market presence [8] - Yifan Pharmaceutical's subsidiary has signed an exclusive agreement with Shangde Yaoyuan for the ACT001 drug, involving a total payment of 1 billion yuan [9] - Yijiahe is exploring the application of "brain-computer interface + embodied intelligent robots" technology in smart healthcare scenarios, having signed a strategic cooperation agreement with Mairande [10]

Core Viewpoint - The A-share market started 2026 on a positive note, with all three major indices rising, indicating a shift from valuation recovery in 2025 to profit-driven growth in 2026 [1][5]. Market Performance - On January 5, 2026, the Shanghai Composite Index rose by 1.38% to 4023.42 points, the Shenzhen Component Index increased by 2.24% to 13828.63 points, and the ChiNext Index saw a rise of nearly 2.9% to 3294.55 points [5]. - The total trading volume reached 2.57 trillion yuan, an increase of over 500 billion yuan compared to the previous trading day, with nearly 4200 stocks rising [5]. Sector Highlights - Key sectors showing strong performance included brain-computer interfaces, insurance, and storage devices, with significant gains in AI applications and emerging industries [2][6]. - The brain-computer interface sector experienced a surge, with related stocks hitting the daily limit, driven by news from overseas about Neuralink's plans for large-scale production [7][9]. Investment Outlook - Analysts predict that the 2026 technology bull market is likely to continue, with a focus on sectors such as technology growth, advanced manufacturing, and cyclical consumption [2][12]. - Investment strategies for 2026 include a balanced approach of high-quality stocks and high-potential sectors, emphasizing technology companies with strong fundamentals and emerging industries [13]. Structural Opportunities - The pharmaceutical sector is expected to see structural opportunities driven by innovation, international expansion, and policy reforms, with a focus on innovative drugs and AI integration in healthcare [14].

1月5日，亿嘉和大宗交易成交111万股，成交额2967.03万元，占当日总成交额的6.1%，成交价26.73 元，较市场收盘价32.67元折价18.18%。 | 19, 224, 2002 7000 11:11 1474 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | | | | 卖出营业部 | 是否为专场 | | 026-01-05 | 亿喜和 | 603666 26.73 | | 2967.03 | 111 | 公園是超出品質問 | 委常委会副员委总 | | Ka | ...

Core Viewpoint - The company is actively exploring the integration of cutting-edge technologies, including "brain-computer interfaces" and embodied intelligent robotics, as a necessary trend in technological development [2] Group 1: Strategic Initiatives - The company has signed a strategic cooperation agreement with Mailland to jointly explore the application possibilities of "brain-computer interface + embodied intelligent robotics" technology in smart health and wellness scenarios [2] Group 2: Application Scenarios - Real-time emotional companionship: The company aims to collect and analyze frontal lobe EEG signals and heart rate variability signals to identify users' emotional states, creating a feedback loop of "monitoring - early warning - intervention" to enhance the emotional care capabilities of robots [2] - Brain-controlled robots: The company is exploring the possibility of interpreting user intentions and commands (such as drinking water or standing up) by combining EEG signals with head position information, thereby enabling precise assistance from robots to improve users' self-care abilities [2]

Group 1 - The stock of Yijiahe closed at 30.31 yuan, with an increase of 1.27% on December 30 [1] - A block trade occurred with a total volume of 1.36 million shares and a transaction amount of 36.6384 million yuan, with a discount rate of -11.12% [1] - The buyer was GF Securities Co., Ltd., and the seller was Huatai Securities Co., Ltd. [1] Group 2 - In the last three months, Yijiahe has had a total of four block trades, amounting to 90.5748 million yuan [1] - Over the past five trading days, the stock has increased by 2.85%, while the net outflow of main funds totaled 28.5414 million yuan [1]

数据显示，华夏基金旗下1只基金位居亿嘉和十大流通股东。华夏中证机器人ETF（562500）三季度增 持63.73万股，持有股数340.38万股，占流通股的比例为1.66%。根据测算，今日浮盈赚取约115.73万 元。 华夏中证机器人ETF（562500）成立日期2021年12月17日，最新规模227.98亿。今年以来收益27.5%， 同类排名2018/4195；近一年收益23.07%，同类排名2220/4179；成立以来亏损0.94%。 华夏中证机器人ETF（562500）基金经理为华龙。 截至发稿，华龙累计任职时间3年132天，现任基金资产总规模359.57亿元，任职期间最佳基金回报 123.21%， 任职期间最差基金回报-15.08%。 12月30日，亿嘉和涨1.14%，截至发稿，报30.27元/股，成交7396.07万元，换手率1.20%，总市值62.21 亿元。 资料显示，亿嘉和科技股份有限公司位于江苏省南京市雨花台区创思路5号，成立日期1999年4月6日， 上市日期2018年6月12日，公司主营业务涉及主要从事特种机器人产品的研发、生产、销售及相关服务, 充分融合移动、感知、操作、人工智能、数据分析 ...

证券代码：603666 证券简称：亿嘉和 公告编号：2025-081 亿嘉和科技股份有限公司 关于非公开发行股票募集资金专户销户完成的公告 为规范公司募集资金的管理和使用，保护投资者的权益，根据相关法律法规 以及中国证监会、上海证券交易所关于募集资金管理的规定，结合公司实际情况， 公司制定了《募集资金管理办法》，并在日常募集资金管理中严格执行上述有关 法律法规及公司规定。 根据《募集资金管理办法》，公司对募集资金实行专户存储管理，在银行分 别开设募集资金专项账户，并与保荐机构、开户银行签署募集资金专项账户三方 监管协议，明确了各方的权利和义务。三方监管协议与上海证券交易所《募集资 金专户存储三方监管协议（范本）》不存在重大差异。公司在使用募集资金时均 严格按照上述三方监管协议执行。 | 序号 | 开户银行 | 银行账号 | 状态 | | --- | --- | --- | --- | | 1 | 上海浦东发展银行股份有限 | 93040078801900001141 | 本次销户 | | | 公司南京新街口支行 | | | | 2 | 中国建设银行股份有限公司 | 32050159503600001525 | ...